An immunoadsorption strategy to produce specific antisera against analogs of human proteins: development of sensitive and specific radioimmunoassays for two analogs of human leptin.
Immunoassay technology is routinely used to measure concentrations of proteins and polypeptides in biological matrices. Increasingly, research efforts have sought to create analogs of human proteins with the aim of improving efficacy or pharmaceutical properties relative to the native protein. Pharmacokinetic assessment of these polypeptide analogs, however, can be greatly confounded by the presence of endogenous native protein. This report describes an immunization and immunoabsorption strategy that was used to create monospecific polyclonal antibodies against analogs of human leptin (LY355101 and LY396623, one and two amino acid changes relative to native human leptin, respectively). Rabbits were immunized with either LY355101 or LY396623. Antisera were screened to determine if any showed increased specificity for the analog relative to native human leptin. Antisera showing increased specificity for the leptin analog were then treated by immunoabsorption against native human leptin, thus depleting human leptin cross-reactivity. The antibodies developed in this process were used in radioimmunoassays. which were validated for use in clinical studies. Both assays proved to be highly specific for LY355101 or LY396623 in the presence of native human leptin. Use of this procedure permitted the measurement of LY355101 and LY396623 pharmacokinetics that were not confounded by the high levels of endogenous human leptin found in obese subjects. This technique has the potential for broad application in the development of assays capable of specifically measuring protein analogs without cross-reactivity to an endogenous substance.
Brown-Augsburger
P
P
Department of Drug Disposition, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA. brown_aug@lilly.com
Masnyk
M
M
Santa
P
P
Gingerich
R L
RL
Bowsher
R R
RR
D000327:Adsorption; D000917:Antibody Formation; D000918:Antibody Specificity; D002138:Calibration; D003429:Cross Reactions; D006801:Humans; D020738:Leptin / Q000031:analogs & derivatives* / Q000276:immunology* / Q000493:pharmacokinetics; D011506:Proteins / Q000276:immunology*; D011863:Radioimmunoassay; D011994:Recombinant Proteins / Q000276:immunology; D015203:Reproducibility of Results; D012996:Solutions; D014614:Vaccines, Synthetic / Q000276:immunology
C418217:LY396623; D020738:Leptin; D011506:Proteins; D011994:Recombinant Proteins; D012996:Solutions; D014614:Vaccines, Synthetic